Search

Displaying results 2991 - 3000 of 9670 in total
  1. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  2. Target

    Probable UbiX-like flavin prenyltransferase

    go.drugbank.com/bio_entities/BE0003027
    TargetEnzymeEscherichia coli O157:H7

    Involved in the non-oxidative decarboxylation and detoxification of phenolic derivatives under both aerobic and anaerobic conditions (PubMed:15979273). Flavin prenyltransferase that catalyzes the synthesis of the prenylated FMN cofactor ...

    Synonyms: PAD
  3. Drug

    Dexmethylphenidate

    go.drugbank.com/drugs/DB06701
    ApprovedInvestigational

    It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181].

  4. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications.

  5. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate.

  6. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor

  7. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  8. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

  9. Drug

    Piboserod

    go.drugbank.com/drugs/DB04873
    Investigational

    Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

  10. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    It is currently under development as topical treatment of psoriasis. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.